SciNeuro Pharmaceuticals Secures $53M Series Funding to Advance Neurodegeneration Therapies
核心洞察
SciNeuro Pharmaceuticals (搜索), founded in 2020, raised $53 million in equity financing led by Arch Venture Partners (搜索) and LAV Capital (搜索) to develop treatments for neurodegenerative disorders.
The company is developing innovative therapies targeting beta amyloid (搜索) and LRRK2 (搜索) proteins for Alzheimer's and Parkinson's diseases, with additional support from a $5 million Michael J. Fox Foundation grant.
The funding represents part of Arch Venture Partners (搜索)' continued investment strategy in nervous system therapeutics, following recent investments totaling over $300 million in neuroscience companies.
SciNeuro Pharmaceuticals (搜索) announced Thursday it has secured $53 million in equity financing to advance its pipeline of treatments for neurodegenerative disorders, marking a significant milestone for the startup founded in 2020. The funding round was led by Arch Venture Partners (搜索) and China-based LAV Capital (搜索), with participation from both new and existing investors.
The proceeds will support SciNeuro's development of drug programs targeting what the company describes as a "range of disease pathways" associated with Alzheimer's and Parkinson's diseases. According to founder and CEO Min Li, the financing "represents a significant milestone for SciNeuro and demonstrates our commitment to advancing the science behind neurodegenerative disease treatments."
Targeting Key Neurodegeneration Proteins
SciNeuro's research focuses on developing innovative therapies directed at critical proteins implicated in neurodegeneration, including beta amyloid (搜索) and LRRK2 (搜索). The LRRK2 protein is strongly linked to Parkinson's disease, representing a promising therapeutic target for the movement disorder that affects millions worldwide.
The company's work is further supported by a recent $5 million non-dilutive research grant from The Michael J. Fox Foundation (搜索) for Parkinson's Research, underscoring the scientific merit of its approach to tackling these challenging neurological conditions.
Strategic Leadership Addition
Concurrent with the funding announcement, SciNeuro appointed Hogan Wan as chief financial officer. Wan brings more than a decade of experience in biopharma corporate finance and investment banking to the role. Most recently, he served as head of investor relations and strategy at Ascentage Pharma (搜索), where he led the cancer drugmaker's initial public offering process.
Arch's Continued Neuroscience Investment Strategy
The investment represents the latest in Arch Venture Partners (搜索)' sustained focus on nervous system therapeutics, an area of drug development known for its particularly challenging success rates. According to BioPharma Dive data, Arch has participated in at least 74 funding rounds since 2022, including 13 in 2025 alone.
SciNeuro joins a growing portfolio of Arch-backed neuroscience companies. The venture firm recently contributed to a $115 million Series C round for Aspen Neuroscience (搜索) that completed last month and participated in a $200 million financing for Tenvie Therapeutics (搜索) in January. This investment activity is expected to continue, as Arch raised $3 billion last year specifically to fund startup companies.
The neurodegeneration space remains one of the most challenging areas in pharmaceutical development, with historically low success rates compared to other therapeutic areas. However, the continued investor interest and funding, exemplified by SciNeuro's latest round, reflects the significant unmet medical need and potential for breakthrough treatments in conditions like Alzheimer's and Parkinson's diseases.